c-MET Protein (AA 25-932) (His tag)

N° du produit ABIN2180660

Détail du produit

Antigène: c-MET (MET) (Met Proto-Oncogene (MET))

Type de proteíne: Recombinant

Activité biologique: Active

Attributs du protein: AA 25-932

Origine: Humain

Source: HEK-293 Cells

Purification/Conjugué: Cette c-MET protéine est marqué à la His tag.

Séquence: AA 25-932

Attributs du produit: rhHGFR is fused with a polyhistidine tag at the C-terminal. The mature form of HGFR is a disulfide-linked heterodimer composed of proteolytically cleaved α and β chain. Each α and β chain has a calculated MW of 32.5 kDa (α chain) and 60 kDa (β chain). The predicted N-terminal is Glu25 (α chain) & Ser308 (β chain). Protein migrates as 45 kDa (α chain) and 85-90 kDa (β chain) in reduced SDS-PAGE resulting from glycosylation.

Pureté: >92 % as determined by SDS-PAGE.

Stérilité: 0.22 μm filtered

niveau d'endotoxine: Less than 1.0 EU per μg by the LAL method.

Information d'application

Restrictions: For Research Use only

Stockage

Format: Lyophilized

Buffer: PBS, pH 7.4

Conseil sur la manipulation: Please avoid repeated freeze-thaw cycles.

Stock: -20 °C

Stockage commentaire: No activity loss was observed after storage at: In lyophilized state for 1 year (4 °C-8 °C), After reconstitution under sterile conditions for 1 month (4 °C-8 °C) or 3 months (-20 °C to -70 °C).

Détail du antigène

Antigène: c-MET (MET) (Met Proto-Oncogene (MET))

Autre désignation: HGF R (MET Produits)

Synonymes: AUTS9 Protein, HGFR Protein, RCCP2 Protein, c-Met Protein, AI838057 Protein, HGF Protein, Par4 Protein, Hgfr Protein, c-met Protein, MET Protein, C-MET Protein, met Protein, met-A Protein, MET proto-oncogene, receptor tyrosine kinase Protein, met proto-oncogene Protein, MET proto-oncogene, receptor tyrosine kinase L homeolog Protein, MET Protein, Met Protein, met.L Protein

Sujet: Hepatocyte growth factor receptor (HGFR) is also known as mesenchymal-epithelial transition factor (MET), c-Met, and is a glycosylated receptor tyrosine kinase that plays a central role in epithelial morphogenesis and cancer development. HGFR protein possesses tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. HGFR is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymal origin. Upon HGF stimulation, HGFR induces several biological responses that collectively give rise to a program known as invasive growth. Abnormal HGFR activation in cancer correlates with poor prognosis, where aberrantly active HGFR triggers tumor growth, formation of new blood vessels (angiogenesis) that supply the tumor with nutrients, and cancer spread to other organs (metastasis). HGFR is deregulated in many types of human malignancies, including cancers of kidney, liver, stomach, breast, and brain. Normally, only stem cells and progenitor cells express HGFR, However, cancer stem cells are thought to hijack the ability of normal stem cells to express HGFR, and thus become the cause of cancer persistence and spread to other sites in the body. Various mutations in the HGFR gene are associated with papillary renal carcinoma. HGFR mediates a complex program known as invasive growth. Activation of HGFR triggers mitogenesis, and morphogenesis.

Poids moléculaire: 102.7 kDa

Pathways: Signalisation RTK, Carbohydrate Homeostasis, Synaptic Membrane, Signaling of Hepatocyte Growth Factor Receptor